---
title: "Jazz Pharma Reports Positive Topline Data From Phase 3 IMforte Maintenance Study In ES-SCLC"
description: "Jazz Pharmaceuticals plc (JAZZ) announced positive top-line results from the Phase 3 IMforte study for adults with extensive-stage small cell lung cancer (ES-SCLC). The study evaluated the combination"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/216863023.md"
published_at: "2024-10-15T12:26:17.000Z"
---

# Jazz Pharma Reports Positive Topline Data From Phase 3 IMforte Maintenance Study In ES-SCLC

> Jazz Pharmaceuticals plc (JAZZ) announced positive top-line results from the Phase 3 IMforte study for adults with extensive-stage small cell lung cancer (ES-SCLC). The study evaluated the combination of Zepzelca and atezolizumab, showing significant improvements in overall survival and progression-free survival compared to atezolizumab alone. The combination was well tolerated, with no new safety signals. Jazz plans to submit a supplemental New Drug Application in the first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC.

Jazz Pharmaceuticals plc (JAZZ) Tuesday announced positive top-line results from the Phase 3 IMforte study in adults with extensive-stage small cell lung cancer (ES-SCLC).

The study is designed to evaluate Zepzelca in combination with atezolizumab compared to atezolizumab alone for the maintenance treatment for adults with ES-SCLC. Topline data from the study showed that treatment with Zepzelca and atezolizumab combination demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to treatment with atezolizumab alone.

Further, the combination was generally well tolerated. The preliminary safety data in the ongoing trial, which is sponsored by Roche and co-funded by Jazz Pharmaceuticals, was consistent with the known safety profiles of Zepzelca and atezolizumab with no new safety signals observed in the combination arm.

Zepzelca, an approved treatment for metastatic small cell lung cancer (SCLC), is developed by PharmaMar and sold by Jazz in the U.S. Roche's immunotherapy drug atezolizumab is indicated for the treatment of various cancers including NSCLC, SCLC, among others.

Jazz plans to submit supplemental New Drug Application in first half of 2025 for the Zepzelca, atezolizumab combination therapy as a first-line maintenance treatment for ES-SCLC.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [JAZZ.US - Jazz Pharma](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results | Jazz Pharmaceuticals (JAZZ) has gained attention following positive Phase 3 results for its HER2-targeted drug Ziihera i | [Link](https://longbridge.com/en/news/271933572.md) |
| What Analysts Are Saying About Jazz Pharmaceuticals Stock | Analysts have provided mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past three months, with 11 analysts | [Link](https://longbridge.com/en/news/272265895.md) |
| Jazz Pharmaceuticals Showcases Rare Disease Breakthroughs and Growth Strategy in New Presentation | Jazz Pharmaceuticals plc presented at the 44th Annual J.P. Morgan Healthcare Conference, showcasing its achievements and | [Link](https://longbridge.com/en/news/272449426.md) |
| Jazz Pharmaceuticals Completes Acquisition of Chimerix | Jazz Pharmaceuticals has acquired Chimerix, integrating it into its corporate strategy. The acquisition includes the Pha | [Link](https://longbridge.com/en/news/272282470.md) |
| Jazz Pharmaceuticals Announce Positive Efficacy From Ziihera Phase 3 Trial | Jazz Pharmaceuticals PLC :ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS ACHIEVE UNPRECEDENTED RESULTS IN FIRST-LINE HER2+ LOC | [Link](https://longbridge.com/en/news/271691426.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
